PLRZ polyrizon-biotech.com: ערך חשבונאי למניה

Polyrizon Ltd (PLRZ) revenues rely on the market launch of barrier agents, specifically Bio-Layer nasal gels. The book value per share trend demonstrates capital accumulation, where the current status is 11.43. Trap and Protect technology establishes a hygiene standard by blocking viruses. Meanwhile, the project's success is tied to biopolymer trials and stable long-term capital.

Polyrizon Ltd (PLRZ) leadership in developing polymer barriers for mucosal protection makes its market capitalization dependent on the value of intangible assets and patents. Analyzing the total book value, an investor can see the residual value of net assets per share, which allows for an assessment of the business's intrinsic value; however, the long-term consensus requires comparing this metric with current operating profitability.